Effectiveness of inactivated influenza vaccine in children by vaccine dose, 2013–18

• Published in: Vaccine Vol. 37; no. 30; pp. 4047 - 4054
• Main Authors: Shinjoh, Masayoshi, Sugaya, Norio, Furuichi, Munehiro, Araki, Eriko, Maeda, Naonori, Isshiki, Kyohei, Ohnishi, Takuma, Nakamura, Shoko, Yamada, Go, Narabayashi, Atsushi, Nishida, Mitsuhiro, Taguchi, Nobuhiko, Nakata, Yuji, Yoshida, Makoto, Tsunematsu, Kenichiro, Shibata, Meiwa, Munenaga, Takeshi, Hirano, Yasuhiro, Ookawara, Ichiro, Sekiguchi, Shinichiro, Kobayashi, Yasuaki, Yamaguchi, Yoshio, Yoshida, Naoko, Mitamura, Keiko, Takahashi, Takao
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 09.07.2019; Elsevier Limited
• Subjects: Age; Allergy and Immunology; Children; Diagnostic systems; Drug dosages; Effectiveness; Fever; Hospitalization; hospitals; Immunization; Influenza; Influenza A; Influenza B; Influenza vaccine; influenza vaccines; Japan; Licenses; Maternal & child health; Ratios; Seasons; Studies; Test-negative case control; Vaccine dose; Vaccine efficacy; Vaccines; Japan; Hospitalization; Effectiveness; Children; Test-negative case control; Influenza vaccine; Vaccine dose
• ISSN: 0264-410X; 1873-2518; 1873-2518
• DOI: 10.1016/j.vaccine.2019.05.090

•Both one- and two-doses regimens of inactivated flu vac are effective for children.•Both regimens reduced cases involving hospitalization due to influenza A.•The two-dose regimen was more effective against influenza B in some seasons. We assessed the vaccine effectiveness (VE) of inactivated influenza vaccine (IIV) by vaccine dose in children aged 6 months to 12 years for whom two doses are recommended in Japan to ascertain the appropriate vaccine doses. VE was assessed according to a test-negative case-control design based on rapid influenza diagnostic test (RIDT) results. Children aged 6 months to 12 years with a fever ≥38 °C who had received an RIDT in outpatient clinics of 24 hospitals were enrolled for all five seasons since 2013/14. VE by vaccine dose (none vs. once or twice, and once vs. twice) was analyzed. In the dose analysis, 20,033 children were enrolled. Both one- and two-dose regimens significantly reduced cases in preventing any influenza, influenza A, and influenza B, but there was no significant difference in adjusted VE between one- and two-dose regimens overall (adjusted OR, 0.560 [95% CI, 0.505–0.621], 0.550 [95% CI, 0.516–0.586]), 0.549 [95% CI, 0.517–0.583], and 1.014 [95% CI, 0.907–1.135], for none vs. once, none vs. twice, none vs. once or twice, and once vs. twice for any influenza, respectively). Both one- and two-dose regimens significantly reduced cases with any influenza and influenza A every season. Also, both regimens significantly reduced cases of any influenza, influenza A, and influenza B among children aged 1–12 years, especially among those aged 1–5 years. In the 2013/14, 2015/16, and 2016/17 seasons, however, only the two-dose regimen was significantly effective in preventing influenza B. Both one- and two-dose regimens significantly reduced cases involving hospitalization due to any influenza and influenza A. Both one- and two-doses regimens of IIV were effective in preventing influenza for children aged 6 months to 12 years. The two-dose regimen was more effective against influenza B in some seasons.